Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 and ≤90 years.~2. Informed consent obtained from subject or acceptable subject surrogate (i.e. next of kin, or legal representative).~3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.~4. Baseline NIHSS obtained prior to randomization ≥ 8 points and ≤ 25 points.~5. Pre-stroke mRS score of 0 - 2.~6. Treatable as soon as possible and at least within 6 hours of symptom onset, defined as point in time when the subject was last seen well (at baseline).~7. Patients should be candidates to receive EVT treatment with or without i.v. rt-PA.~8. Occlusion (TICI 0 or TICI 1 flow), of the terminal internal carotid artery (TICA), M1 or M2 segments of the middle cerebral artery, suitable for mechanical embolectomy, confirmed on Computed Tomography Angiography.~9. The following imaging criteria should also be met on admission neuroimaging:~   1. MRI criterion: volume of DWI (Diffusion-weighted Imaging) restriction ≥5 mL and ≤70 mL OR~  2. CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT AND infarct core determined on admission CTPerfusion by Cerebral Blood Flow\<30%: ≥5 mL and ≤70 mL.~10. The subject has an indication and is planned to receive endovascular treatment of stroke according to the European Stroke Organization Guidelines.~Exclusion Criteria:~1. Subject has suffered a stroke in the past 1 year.~2. Occlusion (TICI 0 or TICI 1 flow) of the basilar or vertebral or posterior or anterior cerebral arteries.~3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.~4. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR (international normalized ratio)\>3.0.~5. Baseline platelet count \<50,000/μL.~6. Baseline blood glucose of \<50 mg/dL or \>400 mg/dL.~7. Severe, sustained hypertension (systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg).~8. Serious, advanced, or terminal illness with anticipated life expectancy of less than 1 year.~9. Subjects with identifiable intracranial tumors.~10. History of life-threatening allergy (more than rash) to contrast medium.~11. Known renal insufficiency with creatinine ≥3 mg/dL or Glomerular Filtration Rate (GFR) \<30 mL/min.~12. Cerebral vasculitis.~13. Evidence of active systemic infection.~14. Known current use of cocaine at time of treatment.~15. Patient participating in a study involving an investigational drug or device that would impact this study.~16. Patients that are unlikely to be available for a 90-day follow-up (e.g. no fixed home address, visitor from overseas).~17. Female who is pregnant or lactating or has a positive pregnancy test at time of admission.~18. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).~19. Significant mass effect with midline shift.~20. Suspicion of aortic dissection presumed septic embolus, or suspicion of bacterial endocarditis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Phase Ib ApTOLL (Type: ACTIVE_COMPARATOR): ApTOLL is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include six patients.
- Phase Ib Placebo (Type: PLACEBO_COMPARATOR): Placebo is administered intravenously in a single ascending dose pattern in four dose levels (0.025mg/kg - 0.2mg/kg). All levels include two patients.
- Phase IIa ApTOLL (Type: ACTIVE_COMPARATOR): ApTOLL is administered intravenously (two doses selected in Phase Ib). The two dose levels include 35 patients each one.
- Phase IIa Placebo (Type: PLACEBO_COMPARATOR): Placebo is administered intravenously in one arm which includes 49 patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).